harmacare
Discussion and Debate
Commentary: Which Principles Should Apply for a National Strategy on Rare Diseases?
Marc-André Gagnon
Research Paper
Conflicts of Interest of Canadian Medical School Deans: A Cross-Sectional Study
Joel Lexchin
Discussion and Debate
Federal Funding for Expensive Drugs for Rare Diseases: How Do We Pick and Choose?
Joel Lexchin and Sandra Sirrs
Discussion and Debate
Commentary: The Conflict Between Protecting Public Health and Raising Tax Revenue
Wayne Hall
Discussion and Debate
Five Years After Cannabis Legalization, Is It Time to Ease Restrictions on Promotion?
Jean-François Crépault, Sergio Rueda and Victor Tang
Research Paper
Methadone Prescribing Regulation for Opioid Use Disorder in Canada: Evidence for an East–West Policy Divide
Chloe Campbell, Kellia Chiu and Abhimanyu Sud
Research Paper
Value in Primary Care: Evidence from the Canadian Primary Care Sentinel Surveillance Network
Sabrina T. Wong, Rachael Morkem, Ayat Salman, David Barber and Jerome A. Leis
Discussion and Debate
Multinational Pharmaceutical Companies Shortchange Canada in Research and Development Investments: Is It Time to Pursue Other Options?
Shoo K. Lee, Sukhy K. Mahl, Jessica J. Green and Joel Lexchin
Discussion and Debate
Commentary: Reconsidering Pharmaceutical Research and Development Investments
Marc-André Gagnon